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Background
A direct pharmacological stimulation of soluble guany-
late cyclase (sGC) is an emerging therapeutic approach
to the management of various cardiopulmonary disor-
ders associated with endothelial dysfunction. Novel sGC
stimulators, including riociguat (BAY 63-2521), have a
dual mode of action: they sensitize sGC to endogenously
produced nitric oxide (NO) and also directly stimulate
sGC independently of NO. Little is known about their
effects on tissue remodelling and degeneration and sur-
vival in experimental malignant hypertension.
Results
Mortality, hemodynamics and biomarkers of tissue remo-
delling and degeneration were assessed in Dahl salt-sensi-
tive rats maintained on a highs a l td i e ta n dt r e a t e dw i t h
riociguat (3 or 10 mg/kg daily) for 14 weeks. Riociguat
markedly attenuated systemic hypertension, improved
systolic heart function and increased survival (from 33%
in the placebo group to 85% in the treated animals). His-
tological examination of the heart and kidneys revealed
that riociguat significantly ameliorated fibrotic tissue
remodelling and degeneration. Correspondingly, mRNA
expression of the pro-fibrotic biomarkers osteopontin
(OPN), tissue inhibitor of matrix metalloproteinase-1
(TIMP-1) and plasminogen activator inhibitor-1 (PAI-1)
in the myocardium and the renal cortex was attenuated
by riociguat. In addition, riociguat reduced plasma and
urinary levels of OPN, TIMP-1, and PAI-1.
Conclusion
Stimulation of sGC by riociguat markedly improves sur-
vival and attenuates systemic hypertension and systolic
dysfunction, as well as fibrotic tissue remodelling in the
myocardium and the renal cortex in a rodent model of
pressure and volume overload. These findings suggest a
therapeutic potential of sGC stimulators in providing
organ protection in diseases associated with impaired
cardiovascular and renal functions.
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